Drug Profile

67Cu SAR bisPSMA - Clarity Pharmaceuticals

Alternative Names: ⁶⁷Cu SAR-bisPSMA; Cu-67 SAR-bisPSMA

Latest Information Update: 19 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Clarity Pharmaceuticals
Class Antineoplastics; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Prostate cancer

Most Recent Events

05 Mar 2025 Updated efficacy and adverse event data from a phase I/IIa trial in Prostate cancer released by Clarity Pharmaceuticals
19 Feb 2025 67Cu SAR bisPSMA - Clarity Pharmaceuticals receives Fast Track designation for Prostate cancer [Parenteral] (Hormone refractory, Metastatic disease) in USA
19 Feb 2025 Clarity Pharmaceuticals plans the safety review committee meeting in March 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com